Tag: Aimmune Therapeutics
Seres Therapeutics gets FDA priority review designation for SER-109 in rCDI
Seres Therapeutics has secured priority review designation from the US Food and Drug Administration (FDA) for SER-109, its investigational oral microbiome therapeutic for the prevention ... Read More
Nestlé to fully own Aimmune Therapeutics through $2bn deal
Nestlé will take full ownership of Aimmune Therapeutics, the developer of FDA approved peanut allergy drug Palforzia, by acquiring the remaining stake of 74.4% in ... Read More
First patients being treated with Aimmune’s PALFORZIA peanut allergy drug
Aimmune Therapeutics said that the first patients in the US are being treated with the recently FDA approved peanut allergy drug PALFORZIA . The California-based ... Read More
Nestlé increases stake in Aimmune Therapeutics after Palforzia FDA approval
Aimmune Therapeutics, which has recently bagged approval from the US Food and Drug Administration (FDA) for its peanut allergy drug PALFORZIA (formerly AR101), has secured ... Read More
Aimmune Therapeutics bags Palforzia FDA approval for peanut allergy
Palforzia FDA approval : Aimmune Therapeutics has been granted approval from the US Food and Drug Administration (FDA) for Palforzia for the treatment of peanut ... Read More